OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement
Veeva Systems (NYSE:VEEV) today announced that OPKO Health (NASDAQ:OPK), a diagnostic and pharmaceutical company, selected multichannel Veeva CRM to enable field teams to engage in relevant, timely, and compliant interactions with healthcare professionals (HCPs) through preferred channels. Veeva CRM gives OPKO Health the most advanced capabilities and complete customer insights.
“Veeva CRM helps our field teams better understand our customers in real time so we can engage more effectively and efficiently in the right channel,” said Adria Parks-Herrera, senior marketing director at OPKO Health. “Switching to multichannel Veeva CRM from our legacy provider will allow us to deliver the very best customer experience and strengthen our relationships with HCPs.”
In addition to Veeva CRM, OPKO Health selected Veeva CLM and Veeva CRM Approved Email for tailored sales calls and compliant emails; Veeva Align for fast, accurate territory alignments and simplified multichannel cycle planning; and Veeva CRM Events Management to run fully integrated live events with greater compliance.
“Life sciences companies, from the largest to emerging biopharmaceuticals, are transforming customer engagement with multichannel Veeva CRM,” said David Logue, senior vice president of commercial strategy at Veeva. “Advanced capabilities in Veeva CRM drive efficiency and effectiveness so OPKO Health can advance its commercial strategy.”
Multichannel Veeva CRM empowers commercial teams with best practices and complete customer insights to transform customer engagement while maintaining compliance. With seamless integration of digital and personal channels, companies extend their reach and engage customers through their channel of choice. See our infographic to learn how Veeva CRM is enabling real-time reps to do more from any device, anywhere.
Additional Information
For more on Veeva CRM, visit veeva.com/eu/CRM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_EU on Twitter: twitter.com/veeva_EU
Like Veeva on Facebook: facebook.com/veevasystems
About OPKO Health
OPKO Health is a diversified healthcare company. In diagnostics, its BioReference Laboratories is the nation's third largest clinical laboratory; GeneDx is a rapidly growing genetic testing business; the 4Kscore® prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with a total PSA test approved by the FDA and testosterone as the most advanced test in development. In its pharmaceutical pipeline, RAYALDEE is its first pharmaceutical product to be marketed. OPKO is headquartered in Miami and has research, development, production, and distribution facilities globally. For more information, visit opko.com.
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 775 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2019 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005034/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 08:00:00 EEST | Press release
An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor. Curatis intends to develop corticorelin to treat PTBE in primary and metasta
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 202523.5.2025 00:43:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company- and investigator-sponsored studies highlighting the company’s focus on advancing differentiated molecules to tackle some of the most challenging cancers. “The new clinical data we are presenting at ASCO showcase our dedication to advancing innovative therapies for a wide range of diseases—spanning from common cancers to rare non-malignant neoplasms,” said Victoria Zazulina, M.D., Head of Development Unit, Oncology, for the Healthcare business of Merck. “From encouraging early data for our lead antibody-drug conjugate, precemtabart tocentecan, in patients with advanced CRC, to new Phase
Cooperation between Topcon Positioning Systems and Amberg Technologies Ltd.22.5.2025 23:17:00 EEST | Press release
Topcon Positioning Systems and Amberg Technologies Ltd. have initiated a close collaboration to enable interoperability between Topcon’s sensor solutions and Amberg Technologies’ software and hardware platforms for rail and tunnel applications. This marks the first step towards offering fully integrated solutions to our shared customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522363239/en/ Luc Le Maire, Senior Vice President, Topcon (left) and Johannes Mueller, CEO, Amberg Technologies. About Topcon Positioning Systems Topcon Positioning Systems is an industry-leading designer, manufacturer and distributor of precision measurement and workflow solutions for the global construction, geospatial and agriculture markets. Topcon Positioning Systems is headquartered in Livermore, California, U.S. (topconpositioning.com, LinkedIn, X, Facebook, Instagram). Its European head office is in Zoetermeer, Netherlands. Topcon Cor
LBT Holdings Ltd. Acquires Gonet Bank & Trust Limited, Introducing Bank of Nassau to Uphold the Finest Traditions of Private Banking22.5.2025 19:29:00 EEST | Press release
LBT Holdings Ltd., in partnership with Gonet SA, is pleased to announce the successful acquisition of Gonet Bank & Trust Limited, a distinguished Bahamas-based private bank formerly owned by Gonet SA. The transaction, which has received full regulatory approval from the Swiss Financial Market Supervisory Authority (FINMA), the Central Bank of The Bahamas (CBOB), and The Securities Commission of The Bahamas (SCB), marks a significant milestone for both organizations. Effective immediately, LBT Holdings Ltd. assumes 100% ownership of Gonet Bank & Trust Limited. As part of this strategic transition, Gonet Bank & Trust Limited will be rebranded as Bank of Nassau 1982 Limited, reflecting its renewed vision and commitment to excellence in private banking and wealth management. This acquisition strengthens the position of all parties in the global financial services sector, enabling expanded service offerings while upholding the highest standards of client-centric banking. Bank of Nassau 1982
PPG highlights continued progress toward 2030 sustainability targets in latest report22.5.2025 16:31:00 EEST | Press release
PPG (NYSE:PPG) today announced continued progress against its near-term 2030 sustainability targets, including reducing greenhouse gas (GHG) emissions throughout its own operations and value chain, and continued improvement in sustainably advantaged product sales driven by customer demand. “Sustainability is core to our purpose and a key enabler of our enterprise growth strategy,” said Peter Votruba-Drzal, PPG vice president, global sustainability. “It is embedded in how we do business by supporting our customers’ success through sustainably advantaged solutions that deliver industry-leading products, improved performance and operational savings, resulting in reduced water, waste and energy use.” Key highlights in PPG’s 2024 Sustainability Report include: 41% of sales from sustainably advantaged products, such as the PPG ENVIRO-PRIME® EPIC200X solution, which enabled a customer’s facility to reduce CO2 emissions by 3,500 metric tons annually. Significant expansion in renewable energy e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom